


# Inflammatory Bowel Disease



**Valerie Vella**  
**Senior Clinical Pharmacist**  
**Mater Dei Hospital**

---




# DEMOGRAPHICS

- ❑ There are approximately 1,600 patients on the Maltese Islands who have inflammatory bowel disease (IBD)
- ❑ This indicates a prevalence of 400 per 100,000 population
- ❑ Higher prevalence of IBD than USA but similar to that in the UK
- ❑ Incidence of Ulcerative Colitis (UC) is 4.5 times that of Crohn's Disease (CD)
- ❑ Men and women are diagnosed in equal numbers



# DEMOGRAPHICS

Number of Schedule V cards issued 1999-2009






---


# COSTS

- IBD is a lifelong condition with a high cost impact on the NHS
  - The lifetime medical costs associated with the care of IBD have been comparable to major chronic diseases such as diabetes mellitus or cancer
  - Medication cost of IBD to the NHS have been estimated at about €1.3 million for the year 2009
-




# Cost of medications used in IBD





# COSTS

- Traditionally drug costs have accounted for about a quarter of total direct health service costs for IBD in Europe
- There are strong arguments both clinically and economically for focussing services towards prompt detection and optimal outpatient management of disease flare-ups and effective maintenance of remission.



# COSTS

- Direct medical costs for patients who have a flare-up compared to those who remained in remission is 20-fold higher
- Good management of the disease means reduced morbidity and mortality in economically active young people with a major impact on economic contribution.

# QUALITY OF LIFE



Patients' rating of health status






---

# OBJECTIVES

- Work in collaboration with MACC to deliver consistent, high-quality care to all patients suffering from IBD.
  - Establish a Malta Registry of IBD patients identifying the IBD population accurately would significantly improve the ability of the NHS to ensure that IBD services are planned and managed effectively.
  - Encourage the development of agreed clinical and patient-reported outcome measures for monitoring the quality of IBD services
  - Encouraging funding and research into IBD
-



---

Thank You

---